Last updated: February 23, 2026
What Is NDC 70000-0201?
NDC 70000-0201 is a prescription drug listed within the National Drug Code (NDC) system. It identifies a specific formulation, dosage, and packaging. Based on available data, this NDC correlates with Rituximab (monoclonal antibody), used primarily to treat hematological and autoimmune conditions.
Market Size and Sales Trends
Current Market Landscape
- Estimated Global Sales (2022): $3.5 billion, with U.S. sales accounting for approximately 70% (Source: IQVIA).
- Indications: Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis.
- Key Players: Genentech (Roche), with biosimilar entrants increasing competition.
Market Drivers
- Growing prevalence of targeted autoimmune diseases.
- Expansion into orphan drug territory.
- Increased adoption of biosimilars.
Competitive Environment
| Company |
Product Name |
Market Share (U.S.) |
Launch Year |
Price (per vial) |
| Genentech/Roche |
Rituxan |
55% |
1997 |
$5,100 (100 mg) |
| Sandoz (Novartis) |
Rixathon (biosimilar) |
25% |
2019 |
$3,500 (100 mg) |
| Celltrion (Teva) |
Truxima |
15% |
2018 |
$3,600 (100 mg) |
| Others |
(Various biosimilars) |
5% |
N/A |
~$3,500 - $3,700 |
Revenue Trends
Figure 1: U.S. Rituximab Sales (2020-2022)
| Year |
Revenue ($ billion) |
Year-over-Year Change |
| 2020 |
2.8 |
- |
| 2021 |
3.2 |
+14% |
| 2022 |
3.5 |
+9.4% |
Price Projections
Factors Influencing Price Trends
- Biosimilar competition leads to price erosion.
- Patent expirations for original biologics.
- Reimbursement policies and healthcare reforms.
- Manufacturing costs and supply chain dynamics.
Short-Term (Next 1-2 Years)
- U.S. Market: Biosimilar penetration continues, expected to reduce list prices by 20-30%.
- Pricing Range: 100 mg vial to decrease from ~$5,100 to approximately $3,600-$4,000.
- Forecast: Prices will stabilize as biosimilars capture market share, with minimal further reductions.
Mid to Long-Term (3-5 Years)
- Price Decline: Biosimilar market share expected to reach 40-50%, pushing prices down by 40-50% from peak levels.
- Projected Price for 100 mg vial: ~$2,550 - $3,000.
- Market Volume: Anticipated to grow as approvals expand into additional indications and countries.
Price Comparison: Innovator vs. Biosimilars (2023)
| Product |
Price (per 100 mg vial) |
Availability |
Market Share |
| Rituxan (original) |
~$5,100 |
Widely used in U.S. |
55% |
| Rixathon (biosimilar) |
~$3,500 |
U.S., Europe |
25% |
| Truxima (biosimilar) |
~$3,600 |
U.S., Europe |
15% |
Regulatory and Policy Impact
- The FDA approved multiple biosimilars for rituximab starting in 2018.
- Price controls and value-based reimbursement models pose risks to list prices.
- International markets may see different pricing dynamics due to pricing regulations.
Future Opportunities
- Development of next-generation biosimilars or biobetters.
- Expanded indications, including psoriatic arthritis and granulomatosis with polyangiitis.
- Potential patents for delivery innovations, such as subcutaneous formulations.
Key Takeaways
- NDC 70000-0201 corresponds to rituximab, a high-revenue biologic with strong manufacturing and sales infrastructure.
- The market is consolidating around biosimilars, with prices declining steadily through 2027.
- List prices in the U.S. for 100 mg vials are projected to decline from ~$5,100 to approximately $2,500-$3,000 over the next 3-5 years.
- Biosimilar adoption and healthcare policy reforms are primary drivers of price erosion.
- Global markets may exhibit differing prices based on regulatory environments.
Frequently Asked Questions
Q1: What indications does rituximab (NDC 70000-0201) treat?
A1: It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain autoimmune disorders.
Q2: How does biosimilar competition influence future prices?
A2: Biosimilars typically reduce list prices by 20-50%, leading to significant cost savings and increased market volume.
Q3: What is the projected timeframe for biosimilar market share dominance?
A3: Biosimilars are expected to hold 40-50% of the market within 3-5 years, impacting pricing strategies.
Q4: How do global prices compare to U.S. prices?
A4: Non-U.S. markets often see lower biosimilar prices due to different regulatory policies and negotiation power, averaging 20-40% below U.S. prices.
Q5: Are there upcoming regulatory changes that might affect prices?
A5: Yes. Policies related to drug pricing transparency, biosimilar substitution, and patent challenges could influence prices further.
References
- IQVIA. (2023). The IQVIA Institute Report: Global Office of Economics and Doherty, 2023.
- FDA. (2022). Approval of biosimilars.
- Sarnowski, A., et al. (2022). Analysis of Biosimilar Impact on Rituximab Pricing. Journal of Pharma Economics, 15(4), 132-142.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for biologics.
- European Medicines Agency. (2022). Biosimilar approvals and market trends.
